The Lancet Oncology in conversation with
by The Lancet Group
Is this your podcast?On the show
From 14 epsHosts
Recent guests
Recent episodes
Tumour-infiltrating lymphocytes in breast cancer with Professor Sherene Loi
Aug 24, 2026
17m 49s
5-year quality of life study of the SUPREMO trial examining chest wall radiotherapy in patients with intermediate-risk breast cancer with Professor Galina Velikova
Jul 27, 2026
11m 48s
Hans Merks on European guidelines for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma
Jun 29, 2026
12m 39s
Hedvig Hricak and Zachary Ward on Cancer workforce—a global crisis: a Lancet Oncology Commission
May 31, 2026
23m 36s
Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
Apr 27, 2026
13m 01s
Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 4 chart positions in 4 markets.
By chart position
- 🇬🇧GB · Medicine#1425K to 30K
- 🇸🇪SE · Medicine#1221K to 10K
- 🇰🇷KR · Medicine#1451K to 10K
- 🇨🇭CH · Medicine#713K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
5K to 30K🎙 ~2x weekly·80 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
10K to 60K🇬🇧50%🇸🇪17%🇰🇷17%+1 more - Active Followers
Loyal subscribers who consistently listen
4K to 24K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 8/24/26 | breast cancertumour-infiltrating lymphocytes+3 | Professor Sherene Loi | International Immuno-Oncology Biomarker Working GroupThe Lancet Oncology+3 | — | tumour-infiltrating lymphocytesbreast cancer+5 | — | 17m 49s | ||
| 7/27/26 | quality of lifechest wall radiotherapy+3 | Professor Galina Velikova | SUPREMO trialThe Lancet+1 | intermediate-risk breast cancer | quality of lifeSUPREMO trial+5 | — | 11m 48s | ||
| 6/29/26 | imagingosteosarcoma+4 | Hans Merks | The Lancet GroupThe Lancet+1 | — | osteosarcomaEwing sarcoma+4 | — | 12m 39s | ||
| 5/31/26 | cancer workforceglobal health crisis+3 | Dr Hedvig HricakDr Zachary Ward | Memorial Sloan Kettering Cancer CenterHarvard TH Chan School of Public Health+2 | New York, NY, USABoston, MA, USA | cancer workforceglobal crisis+3 | — | 23m 36s | ||
| 4/27/26 | quality of lifemetastatic prostate cancer+3 | Professor Fred Saad | Department of Surgery/Urology, University of MontrealThe Lancet Oncology+1 | Montreal, QC, Canada | metastatic hormone-sensitive prostate cancerquality of life+3 | — | 13m 01s | ||
| 3/30/26 | prostate cancertheranostics+4 | James Nagarajah | [177Lu]-PSMA-617-PSMA-617The Lancet Oncology+1 | — | prostate cancerBULLSEYE+4 | — | 10m 55s | ||
| 3/17/26 | oncological imagingradiology+3 | Ali Landman | The Lancet Medical Imaging & Theranostics | Vienna | oncological imagingradiology+3 | — | 15m 00s | ||
| 3/9/26 | breast cancerepidemiological trends+4 | Kayleigh Bhangdia | GBD | 204 countries | breast cancerGBD study+5 | — | 18m 23s | ||
| 2/2/26 | qualitative researchoncology+3 | Dr Dylan GraetzDr Erica Kaye | St Jude Children’s Research HospitalThe Power of Words: Evaluating the Role of Qualitative Methods in Cancer Research | — | qualitative researchoncology+3 | — | 42m 58s | ||
| 12/29/25 | cancer mortalityoccupation+3 | Dr Jesse PlascakDr Marissa Baker | The Ohio State UniversityUniversity of Washington School of Public Health | — | cancermortality rates+6 | — | 23m 47s | ||
| 11/25/25 | digital healthartificial intelligence+3 | Dr Andre PfobProf Peter Dubsky | Heidelberg University HospitalUniversity of Lucerne+1 | — | digital healthartificial intelligence+3 | — | 26m 34s | ||
| 11/2/25 | cancer carehuman dimensions+3 | Dr Gary Rodin | Lancet OncologyThe Lancet Group | — | cancerhuman crisis+4 | — | 10m 46s | ||
| 10/27/25 | clinical trialsbrain metastases+3 | Matthias Preusser | patritumab deruxtecanMedical University of Vienna+1 | Vienna, Austria | TUXEDO-3patritumab deruxtecan+5 | — | 17m 10s | ||
| 9/29/25 | bladder cancerneoadjuvant therapy+4 | Dr Andrea Necchi | Vita-Salute San Raffaele UniversitySan Raffaele Hospital+1 | — | muscle-invasive bladder cancerTAR-200+4 | — | 12m 15s |
Showing 14 of 80
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Chart history for The Lancet Oncology in conversation with
Peaked at #71 in CH, currently #71 in CH.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| CH | — | #71 | #71 | — |
| Sweden | — | #122 | #122 | — |
| United Kingdom | — | #142 | #142 | — |
| South Korea | — | #145 | #145 | — |
Chart Positions
4 placements across 4 markets.
Chart Positions
4 placements across 4 markets.